Document:

Exhibit 10.10

 

 

 

CONSULTING SERVICES AGREEMENT

BETWEEN

XORTX Therapeutics Inc

AND

Mr. Amar Keshri operating as

 

NEXT
LEVEL CONSULTANTS INC.

 

MADE
AS OF 

July 1, 2021 

 

 

    

     

    

[Company
Letterhead] 

 

CONSULTING
AGREEMENT

 

THIS
AGREEMENT made as of July 1, 2021

 

B
E T W E E N:

 

Amar
Keshri operating as NEXT LEVEL CONSULTANTS INC., a corporation incorporated under the laws of Alberta, Canada (hereinafter referred
to as the “Consultant”)

 

OF
THE FIRST PART,

 

-
and -

 

XORTX
Therapeutics Inc. a corporation incorporated under the laws of British Columbia, Canada (hereinafter referred to as the “Corporation”)

 

OF
THE SECOND PART.

 

THIS
AGREEMENT WITNESSES that in consideration of the covenants and agreements contained herein, the parties hereto agree as follows:

 

ARTICLE
One - GENERAL

 

		1.01	Consultant
                                         Services

 

Subject
to the terms and conditions herein, the Corporation shall retain the Consultant to carry out services and the Consultant shall
render the following consultative services to the Corporation:

 

●     
Consultant shall serve as the Chief Financial Officer;

 

and
such other consultative services as may from time to time be agreed upon between the parties.

 

		1.02	Term
                                         of Agreement

 

The
provision of services by the Consultant to the Corporation hereunder shall commence on the July 1, 2021and shall continue for
a period of 12 months and supersedes any prior agreements and will terminate on the July 1, 2022, subject to earlier termination
of this Agreement as set forth in Article Five herein.

 

     

    - 2 - 

    

ARTICLE
Two - REMUNERATION OF CONSULTANT

 

		2.01	Fee
                                         for Services

 

Subject
to Sections 2.04 and 5.03 below, the Corporation shall pay to the Consultant for the services provided under this Agreement a
rate of:

 

- $8,000
Cdn per month to devote 50 % of their efforts on behalf of XORTX Therapeutics Inc. for the period of July 2021.

 

$15,000
Cdn per month to devote 100 % of their efforts on behalf of XORTX Therapeutics Inc. for the period of August 1, 2021.

 

-
and will be eligible for a bonus of up to 30% of the total of the contract at the time of the grant of the bonus, subject to the
discretion of the compensation committee.

 

-
Consultant will be granted 250,000 options, upon execution of this agreement and as determined from time to time, based on the
discretion of the Management and Board Directors, at current market pricing at the time of the grant.

 

		2.02	Expenses

 

Subject
to Section 2.04, the Corporation shall reimburse the Consultant for all reasonable expenses actually and properly incurred by
the Consultant in the performance of the services hereunder provided that such expenses shall be paid in accordance with the normal
practices of the Corporation in force from time to time. Company hereby agrees to reimburse Consultant for all documented reasonable
travel and other out-of-pocket expenses incurred in connection with Consultant’s engagement hereunder, subject to pre-approval
by the Company for individual expenses over $250 and aggregated monthly expenses over $500. A properly filled expense report with
receipts will be required for any expense claim.

 

		2.03	Invoices

 

Payment
shall be made to the Consultant with respect to the services and expenses referred to in Sections 2.01 and 2.02 above within 14
days from receipt by the Corporation of proper invoices and vouchers together with a satisfactory progress report in respect of
such services and expenses, all of which shall be submitted by the Consultant to the Corporation on the last day of each month
during the term of this Agreement.

 

		2.04	Total
                                         Payment

 

The
total amount of the payments to be made to the Consultant pursuant to Sections 2.01 shall not exceed $15,000 Cdn unless previously
authorized by the CEO and upon confirmation by the compensation committee.

 

     

    - 3 - 

    

ARTICLE
Three - COVENANTS OF CONSULTANT

 

		3.01	Services

 

The
Consultant shall render performance of the services hereunder to the best of the Consultant's ability and in a competent and professional
manner.

 

		3.02	Time
                                         of Services

 

The
Consultant shall devote the specified time up to 100% of his time and attention to the business of the Corporation as may be agreed
to by the Consultant and the Corporation. The time of service to be provided hereunder by the Consultant shall be as agreed to
from time to time by the Corporation and the Consultant. Subject to the obligations of the Consultant hereunder, the Consultant
shall be free to offer services to any other person except where there may be a conflict of interest with the Corporation.

 

		3.03	Licences
                                         and Permits

 

The
Consultant shall be responsible for obtaining all necessary licences and permits and for complying with all applicable federal,
provincial and municipal laws, codes and regulations in connection with the provision of the services hereunder and the Consultant
shall when requested provide the Corporation with adequate evidence of his compliance with this Section 3.03.

 

		3.04	Rules
                                         and Regulations

 

The
Consultant shall comply, while on the premises used by the Corporation, with all workplace policies, procedures, rules and regulations,
as amended tome time to time. The Consultant acknowledges that violation of the terms of any of these policies, procedures, rules
or regulations may be subject to discipline by the Corporation, up to and including the early termination of this Agreement.

 

		3.05	Insurance

 

The
Consultant shall pay for and maintain for the benefit of the Consultant and the Corporation, with insurers or through the appropriate
government department and in an amount and in a form acceptable to the Corporation, appropriate insurance concerning the operations
and liabilities of the Consultant relevant to this Agreement including, without limiting the generality of the foregoing, workers'
compensation and unemployment insurance in conformity with applicable statutory requirements in respect of any remuneration payable
by the Consultant to any employees of the Consultant and public liability and property damage insurance.

 

		3.06	Indemnity

 

The
Consultant shall indemnify and save harmless the Corporation from any and against all claims, actions, losses, expenses, costs
or damages of every nature and kind whatsoever which the Corporation or its current and former officers, employees or agents may
suffer as a result of the negligence of the Consultant in the performance or non-performance of this Agreement.

 

     

    - 4 - 

    

		3.07	Non-disclosure

 

(1)          
The Consultant shall not (either during the term of this Agreement or at any time thereafter) disclose any information relating
to the private or confidential affairs of the Corporation or relating to any secrets of the Corporation to any person other than
for the Corporation's purposes and, without limiting the generality of the foregoing, the Consultant shall not (either during
the term of this Agreement or at any time thereafter) disclose information covered by the confidentiality agreement entered into
by the consultant and XORTX Therapeutics, to any person other than for the Corporation's purposes and shall not (either during
the term of this Agreement or at any time thereafter) use for his own purposes or for any purposes other than those of the Corporation
any such information or secrets he may acquire in relation to the business of XORTX Therapeutics. (collectively referred to as
“Confidential Information”).

 

(2)          
For greater clarity, Confidential Information does not include general knowledge you acquire during the term of this Agreement
that is not proprietary to the Corporation, provided that such general knowledge is a product of the Consultant’s memory
and unaided by data, documents, agreements, files or other materials of the Corporation in any form.

 

(3)          
The Consultant shall obtain a written non-disclosure agreement in a form acceptable to the Corporation in respect of the same
information and secrets referred to in Section 3.07(1) from all persons, including but not limited to any employees of the Consultant,
who are in any way involved with the Consultant in the provision of consultative services to the Corporation hereunder and in
the course thereof may have access to any information or secrets referred to in Section 3.07(1) and the Consultant shall provide
the Corporation with executed copies of any such non-disclosure agreement.

 

		3.08	Non-Competition

 

(1)          
The Consultant shall not, without the prior written consent of the Corporation, at any time for a period of:

 

		(a)	48
                                         months;

 

following
the date of termination of this Agreement for whatever reason and with or without cause, either individually or in partnership
or jointly or in conjunction with any person as principal, agent, employee, shareholder (other than minor holding of shares listed
on a recognized Canadian or United States stock exchange that does not exceed 1% of the outstanding shares so listed) or in any
other manner whatsoever carry on or be engaged in or be concerned with or interested in or advise, lend money to, guarantee the
debts or obligations of or permit his name or any part thereof to be used or employed by any person engaged in or concerned with
or interested in within;

 

		(i)	Uric
                                         acid lowering agents; or,

 

     

    - 5 - 

    

		(ii)	Kidney
                                         disease therapies·;

 

the
business [development of uric acid lowering agents or kidney disease therapies or products].

 

(2)          
The Consultant confirms that all restrictions in Section 3.10(1) are reasonable and valid and all defences to the strict enforcement
thereof by the Corporation are waived by the Consultant.

 

(3)          
Sections 3.08(1)(a), (b) and (c) and Sections 3.08(1)(i), (ii) and (iii) are each separate and distinct covenants, severable one
from the other and the greatest of Sections 3.08(1)(a), (b) and (c) and of sections 3.08(1)(i), (ii) and (iii) shall apply unless
such covenant is determined to be invalid or unenforceable, in which case the next greatest shall apply, and so on.

 

		3.09	Inventions
                                         and Patents

 

In
the event the Consultant contributes to any patentable invention as a result of his consultative services to the Corporation hereunder,
any such patentable invention shall be the exclusive property of the Corporation and the Corporation shall have the exclusive
right to file patent applications in the name of the Corporation in connection therewith and the Consultant shall co-operate with
the Corporation and provide all necessary assistance in the filing, assignment and prosecution of such patent applications.

 

ARTICLE
Four - INDEPENDENT CONTRACTORS

 

		4.01	Consultant
                                         not an Employee

 

The
Consultant is not an employee of the Corporation and shall not be entitled to receive from the Corporation any employee related
benefits, either under the Ontario Employment Standards Act, 2000, as amended from time to time, or otherwise. The Corporation
shall not be required to make contributions to unemployment insurance, Canada Pension Plan, workers' compensation and other similar
levies in respect of the fee for services to be paid to the Consultant pursuant to Section 2.01 above.

 

		4.02	Consultant
                                         shall not contract on behalf of Corporation

 

The
Consultant shall not, without the prior written consent of the Corporation, enter into any contract or commitment in the name
of or on behalf of the Corporation or bind the Corporation in any respect whatsoever.

 

ARTICLE
Five - TERMINATION

 

		5.01	Termination
                                         by Corporation or Consultant for Cause

 

The
Corporation or the Consultant may terminate this Agreement at any time in the event of the failure of the other party to comply
with any of the provisions hereunder upon such other party being notified in writing by the party alleging such failure and failing
to remedy such failure within 30 days of receiving such notice.

 

     

    - 6 - 

    

		5.02	Termination
                                         by Corporation or Consultant on Notice

 

The
Corporation or the Consultant may terminate this Agreement upon the giving 30 days written notice to the other party. Notwithstanding
the foregoing, the Corporation may terminate this Agreement immediately upon providing the Consultant with payment of one month
fee for services in lieu of such notice.

 

		5.03	Termination
                                         by Corporation when Payment Limit Reached

 

This
Agreement shall be terminated upon the Corporation giving the Consultant written notice that the total payment limit for this
Agreement as set forth in Section 2.04 hereof has been reached.

 

		5.04	Termination
                                         on Death of Consultant

 

This
Agreement shall be terminated upon the death of the Consultant.

 

		5.05	Provisions
                                         which Operate Following Termination

 

Notwithstanding
any termination of this Agreement for any reason whatsoever and with or without cause, the provisions of Sections 3.06, 3.07,
3.08 and 3.09 and any other provisions of this Agreement necessary to give efficacy thereto shall continue in full force and effect
following any such termination.

 

ARTICLE
Six - INTERPRETATION AND ENFORCEMENT

 

		6.01	Sections
                                         and Headings

 

The
division of this Agreement into Articles and Sections and the insertion of headings are for the convenience of reference only
and shall not affect the construction or interpretation of this Agreement. The terms “this Agreement”, “hereof”,
“hereunder” and similar expressions refer to this Agreement and not to any particular Article, Section or other portion
hereof and include any agreement or instrument supplemental or ancillary hereto. Unless something in the subject matter or context
is inconsistent therewith, references herein to Articles and Sections are to Articles and Sections of this Agreement.

 

		6.02	Number

 

In
this Agreement words importing the singular number only shall include the plural and vice versa and words importing the
masculine gender shall include the feminine and neuter genders and vice versa and words importing persons shall include
individuals, partnerships, associations, trusts, unincorporated organizations and corporations and vice versa.

 

     

    - 7 - 

    

		6.03	Benefit
                                         of Agreement

 

This
Agreement shall enure to the benefit of and be binding upon the heirs, executors, administrators and legal personal representatives
of the Consultant and the successors and assigns of the Corporation respectively.

 

		6.04	Entire
                                         Agreement

 

This
Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and cancels and supersedes
any prior understandings and agreements between the parties hereto with respect thereto. There are no representations, warranties,
forms, conditions, undertakings or collateral agreements, express implied or statutory between the parties other than as expressly
set forth in this Agreement.

 

		6.05	Amendments
                                         and Waivers

 

No
amendment to this Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties hereto.
No waiver of any breach of any term or provision of this Agreement shall be effective or binding unless made in writing and signed
by the party purporting to give the same and, unless otherwise provided in the written waiver, shall be limited to the specific
breach waived.

 

		6.06	Assignment

 

Except
as may be expressly provided in this Agreement, neither party hereto may assign his or its rights or obligations under this Agreement
without the prior written consent of the other party hereto.

 

		6.07	Severability

 

If
any provision of this Agreement is determined to be invalid or unenforceable in whole or in part, such invalidity or unenforceability
shall attach only to such provision or part thereof and the remaining part of such provision and all other provisions hereof shall
continue in full force and effect.

 

		6.08	Notices

 

Any
demand, notice or other communication (hereinafter in this Section 6.08 referred to as a “Communication”) to be made
or given in connection with this Agreement shall be made or given in writing and may be made or given by personal delivery or
by registered mail addressed to the recipient as follows:

 

     

    - 8 - 

    

To
the Consultant:

 

Mr.
Amar Keshri 

NEXT
LEVEL CONSULTANTS INC. 

11Stoneypointe
Place, Calgary, AB, T3L0C9 

Phone
number: 1-403-561-6041 

Email:
amerkeshri@gmail.com

 

To
the Corporation: 

XORTX
Therapeutics Inc 

Suite
4000, 421 – 7th Avenue, Calgary, Alberta, Canada 

adavidoff@xortx.com 

403-607-2621 

Attention:
Dr. Allen Davidoff

 

or
such other address or individual as may be designated by notice by either party to the other. Any Communication made or given
by personal delivery shall be conclusively deemed to have been given on the day of actual delivery thereof and, if made or given
by registered mail, on the · day, other than a Saturday, Sunday or statutory holiday in Ontario, following the deposit
thereof in the mail. If the party giving any Communication knows or ought reasonably to know of any difficulties with the postal
system which might affect the delivery of the mail, any such Communication shall not be mailed but shall be made or given by personal
delivery.

 

		6.09	Governing
                                         Law

 

This
Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable
therein.

 

		6.10	Attornment

 

For
the purpose of all legal proceedings this Agreement shall be deemed to have been performed in the Province of Ontario and the
courts of the Province of Ontario shall have jurisdiction to entertain any action arising under this Agreement. The Corporation
and the Consultant each hereby attorns to the jurisdiction of the courts of the Province of Ontario provided that nothing herein
contained shall prevent the Corporation from proceeding at its election against the Consultant in the courts of any other province
or country.

 

     

    - 9 - 

    

		6.11	Copy
                                         of Agreement

 

The
Consultant hereby acknowledges receipt of a copy of this Agreement duly signed by the Corporation.

 

IN
WITNESS WHEREOF the parties have executed this Agreement.

 

	SIGNED,
    SEALED AND DELIVERED	 	)	 	 
	in
    the presence of:	 	)	 	 
	 	 	)	 	 
	 	 	)	 	 
	Witness	 	)	Mr.
Amar Keshri 

        amerkeshri@gmail.com 
	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	Per:	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	Dr.
Allen Davidoff, CEO and President 

        XORTX
        Therapeutics Inc.

         
	 

 

     

    - 10 - 

    

Schedule
“A”

 

Position
Summary:

 

The
Chief Financial Officer (CFO) of a company has primary responsibility for the planning, implementation, managing and running of
all the finance activities of a company, including business planning, budgeting, forecasting and negotiations. The CFO job description
should also extend to obtaining and maintaining investor relations and partnership compliance.

 

CFO
duties and responsibilities of the job

 

As
part of an executive management team, the CFO will have interaction with various members of a company, both senior and junior.
A CFO job description should include:

 

		●	Providing
leadership, direction and management of the finance and accounting team

 

		●	Providing
strategic recommendations to the CEO/president and members of the executive management team

 

		●	Managing
the processes for financial forecasting and budgets, and overseeing the preparation of all financial reporting

 

		●	Advising
on long-term business and financial planning

 

		●	Establishing
and developing relations with senior management and external partners and stakeholders

 

		●	Reviewing
all formal finance, HR and IT related procedures

 

		●	Must
be willing to travel on behalf of the company at least 20% of the time when required, per quarter.

 

    

     

    

TABLE
OF CONTENTS

 

CONSULTING
AGREEMENT

 

	ARTICLE
    One - GENERAL	1
	 	 
	1.01	Consultant Services	1
	1.02	Term of Agreement	1
	 	 	 
	ARTICLE
    Two - REMUNERATION OF CONSULTANT	2
	 	 
	2.01	Fee for Services	2
	2.02	Expenses	2
	2.03	Invoices	2
	2.04	Total Payment	2
	 	 	 
	ARTICLE
    Three - COVENANTS OF CONSULTANT	3
	 	 
	3.01	Services	3
	3.02	Time of Services	3
	3.03	Licences and Permits	3
	3.04	Rules and Regulations	3
	3.05	Insurance	3
	3.06	Indemnity	3
	3.07	Non-disclosure	4
	3.08	Non-Competition	4
	3.09	Inventions and Patents	5
	 	 	 
	ARTICLE
    Four - INDEPENDENT CONTRACTORS	5
	 	 
	4.01	Consultant not an Employee	5
	4.02	Consultant shall not contract on behalf
of Corporation	5
	 	 	 
	ARTICLE
    Five - TERMINATION	5
	 	 
	5.01	Termination by Corporation or Consultant for Cause	5
	5.02	Termination by Corporation or Consultant on Notice	6
	5.03	Termination by Corporation when Payment Limit
Reached	6
	5.04	Termination on Death of Consultant	6
	5.05	Provisions which Operate Following Termination	6
	 	 	 
	ARTICLE
    Six - INTERPRETATION AND ENFORCEMENT	6
	 	 
	6.01	Sections and Headings	6
	6.02	Number	6
	6.03	Benefit of Agreement	7
	6.04	Entire Agreement	7
	6.05	Amendments and Waivers	7
	6.06	Assignment	7
	6.07	Severability	7
	6.08	Notices	7
	6.09	Governing Law	8
	6.10	Attornment	8
	6.11	Copy of Agreement	9Exhibit 10.12

 

 

 

 

CONSULTING
AGREEMENT

BETWEEN

XORTX Therapeutics Inc

AND Haworth Biopharmaceutical 

Consulting Services Inc.

 

MADE
AS OF

July 1, 2021

 

 

		XORTX
                                         Therapeutics
                                         Inc.

                                         4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada
                                         T2P 4K9

                                                 

        T
        + 1 403 455 7717  | 
        xortx.com  |  CSE : XRX

 

     

     

    

 

 

CONSULTING
AGREEMENT

 

THIS
AGREEMENT made as of July 1, 2021

 

B
E T W E E N:

 

Stephen
Haworth, of the State of Pennsylvania

(hereinafter referred to as the “Consultant”)

 

OF
THE FIRST PART,

 

-
and -

 

XORTX
Therapeutics Inc. a corporation incorporated under the laws of British Columbia, Canada

(hereinafter referred to as the “Corporation”)

 

OF
THE SECOND PART.

 

THIS
AGREEMENT WITNESSES that in consideration of the covenants and agreements contained herein, the parties hereto agree as follows:

 

ARTICLE
One - GENERAL

 

		1.01	Consultant
                                         Services

 

Subject
to the terms and conditions herein, the Corporation shall retain the Consultant to carry out services and the Consultant shall
render the following consultative services to the Corporation:

 

●;
Consultant shall serve as the Chief Medical Officer;

 

and
such other consultative services as may from time to time be agreed upon between the parties.

 

		1.02	Term
                                         of Agreement

 

The
provision of services by the Consultant to the Corporation hereunder shall commence on the July 1, 2021 and shall continue
for a period of 12 months and supersedes any prior agreements and will terminate on the February 1, 2022, subject to earlier termination
of this Agreement as set forth in Article Five herein.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

ARTICLE
Two - REMUNERATION OF CONSULTANT

 

		2.01	Fee
                                         for Services

 

Subject
to Sections 2.04 and 5.03 below, the Corporation shall pay to the Consultant for the services provided under this Agreement a
the rate of:

 

-                        $11,700
USD per month to devote 100 % of their efforts on behalf of XORTX Therapeutics Inc.

 

-  and will be eligible for a bonus of up to 30% of the total of the contract at the time of the grant of the bonus, subject to the
discretion of the compensation committee.

 

-  and will be eligible for

 

-  Consultant will be granted 250,000 options, upon execution of this agreement and as determined from time to time, based on the
discretion of the Management and Board Directors, at current market pricing at the time of the grant.

 

		2.02	Expenses

 

Subject
to Section 2.04, the Corporation shall reimburse the Consultant for all reasonable expenses actually and properly incurred by
the Consultant in the performance of the services hereunder provided that such expenses shall be paid in accordance with the normal
practices of the Corporation in force from time to time. Company hereby agrees to reimburse Consultant for all documented reasonable
travel and other out-of-pocket expenses incurred in connection with Consultant’s engagement hereunder, subject to pre-approval
by the Company for individual expenses over $250 and aggregated monthly expenses over $500. A properly filled expense report with
receipts will be required for any expense claim.

 

		2.03	Invoices

 

Payment
shall be made to the Consultant with respect to the services and expenses referred to in Sections 2.01 and 2.02 above within 14
days from receipt by the Corporation of proper invoices and vouchers together with a satisfactory progress report in respect of
such services and expenses, all of which shall be submitted by the Consultant to the Corporation on the last day of each month
during the term of this Agreement.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

		2.04	Total
                                         Payment

 

The
total amount of the payments to be made to the Consultant pursuant to Sections 2.01 and 2.02 shall not exceed $11,700 USD unless
previously authorized by the CEO and upon confirmation by the compensation committee.

 

ARTICLE
Three - COVENANTS OF CONSULTANT

 

		3.01	Services

 

The
Consultant shall render performance of the services hereunder to the best of the Consultant’s ability and in a competent and professional
manner.

 

		3.02	Time
                                         of Services

 

The
Consultant shall devote 100% of his time and attention to the business of the Corporation as may be agreed to by the Consultant
and the Corporation. The time of service to be provided hereunder by the Consultant shall be as agreed to from time to time by
the Corporation and the Consultant. Subject to the obligations of the Consultant hereunder, the Consultant shall be free to offer
services to any other person except where there may be a conflict of interest with the Corporation.

 

		3.03	Licences
                                         and Permits

 

The
Consultant shall be responsible for obtaining all necessary licences and permits and for complying with all applicable federal,
provincial and municipal laws, codes and regulations in connection with the provision of the services hereunder and the Consultant
shall when requested provide the Corporation with adequate evidence of his compliance with this Section 3.03.

 

		3.04	Rules
                                         and Regulations

 

The
Consultant shall comply, while on the premises used by the Corporation, with all workplace policies, procedures, rules and regulations,
as amended tome time to time. The Consultant acknowledges that violation of the terms of any of these policies, procedures, rules
or regulations may be subject to discipline by the Corporation, up to and including the early termination of this Agreement.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

		3.05	Insurance

 

The
Consultant shall pay for and maintain for the benefit of the Consultant and the Corporation, with insurers or through the appropriate
government department and in an amount and in a form acceptable to the Corporation, appropriate insurance concerning the operations
and liabilities of the Consultant relevant to this Agreement including, without limiting the generality of the foregoing, workers’
compensation and unemployment insurance in conformity with applicable statutory requirements in respect of any remuneration payable
by the Consultant to any employees of the Consultant and public liability and property damage insurance.

 

		3.06	Indemnity

 

The
Consultant shall indemnify and save harmless the Corporation from any and against all claims, actions, losses, expenses, costs
or damages of every nature and kind whatsoever which the Corporation or its current and former officers, employees or agents may
suffer as a result of the negligence of the Consultant in the performance or non-performance of this Agreement.

 

		3.07	Non-disclosure

 

(1)          
The Consultant shall not (either during the term of this Agreement or at any time thereafter) disclose any information relating
to the private or confidential affairs of the Corporation or relating to any secrets of the Corporation to any person other than
for the Corporation’s purposes and, without limiting the generality of the foregoing, the Consultant shall not (either during
the term of this Agreement or at any time thereafter) disclose information covered by the confidentiality agreement entered into
by the consultant and XORTX Therapeutics, to any person other than for the Corporation’s purposes and shall not (either during
the term of this Agreement or at any time thereafter) use for his own purposes or for any purposes other than those of the Corporation
any such information or secrets he may acquire in relation to the business of XORTX Therapeutics. (collectively referred to as
“Confidential Information”).

 

(2)          
For greater clarity, Confidential Information does not include general knowledge you acquire during the term of this Agreement
that is not proprietary to the Corporation, provided that such general knowledge is a product of the Consultant’s memory
and unaided by data, documents, agreements, files or other materials of the Corporation in any form.

 

(3)          
The Consultant shall obtain a written non-disclosure agreement in a form acceptable to the Corporation in respect of the same
information and secrets referred to in Section 3.07(1) from all persons, including but not limited to any employees of the Consultant,
who are in any way involved with the Consultant in the provision of consultative services to the Corporation hereunder and in
the course thereof may have access to any information or secrets referred to in Section 3.07(1) and the Consultant shall provide
the Corporation with executed copies of any such non-disclosure agreement.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

		3.08	Non-Competition

 

(1)          
The Consultant shall not, without the prior written consent of the Corporation, at any time for a period of:

 

		(a)	48
                                         months;

 

following
the date of termination of this Agreement for whatever reason and with or without cause, either individually or in partnership
or jointly or in conjunction with any person as principal, agent, employee, shareholder (other than minor holding of shares listed
on a recognized Canadian or United States stock exchange that does not exceed 1% of the outstanding shares so listed) or in any
other manner whatsoever carry on or be engaged in or be concerned with or interested in or advise, lend money to, guarantee the
debts or obligations of or permit his name or any part thereof to be used or employed by any person engaged in or concerned with
or interested in within;

 

		(i)	Uric
                                         acid lowering agents; or,

 

		(ii)	Kidney
                                         disease therapies●;

 

the
business [development of uric acid lowering agents or kidney disease therapies or products].

 

(2)          
The Consultant confirms that all restrictions in Section 3.10(1) are reasonable and valid and all defences to the strict enforcement
thereof by the Corporation are waived by the Consultant.

 

(3)          
Sections 3.08(1)(a), (b) and (c) and Sections 3.08(1)(i), (ii) and (iii) are each separate and distinct covenants, severable one
from the other and the greatest of Sections 3.08(1)(a), (b) and (c) and of sections 3.08(1)(i), (ii) and (iii) shall apply unless
such covenant is determined to be invalid or unenforceable, in which case the next greatest shall apply, and so on.

 

		3.09	Inventions
                                         and Patents

 

In
the event the Consultant contributes to any patentable invention as a result of his consultative services to the Corporation hereunder,
any such patentable invention shall be the exclusive property of the Corporation and the Corporation shall have the exclusive
right to file patent applications in the name of the Corporation in connection therewith and the Consultant shall co-operate with
the Corporation and provide all necessary assistance in the filing, assignment and prosecution of such patent applications.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

ARTICLE
Four - INDEPENDENT CONTRACTORS

 

		4.01	Consultant
                                         not an Employee

 

The
Consultant is not an employee of the Corporation and shall not be entitled to receive from the Corporation any employee related
benefits, either under the Ontario Employment Standards Act, 2000, as amended from time to time, or otherwise. The Corporation
shall not be required to make contributions to unemployment insurance, Canada Pension Plan, workers’ compensation and other similar
levies in respect of the fee for services to be paid to the Consultant pursuant to Section 2.01 above.

 

		4.02	Consultant
                                         shall not contract on behalf of Corporation

 

The
Consultant shall not, without the prior written consent of the Corporation, enter into any contract or commitment in the name
of or on behalf of the Corporation or bind the Corporation in any respect whatsoever.

 

ARTICLE
Five - TERMINATION

 

		5.01	Termination
                                         by Corporation or Consultant for Cause

 

The
Corporation or the Consultant may terminate this Agreement at any time in the event of the failure of the other party to comply
with any of the provisions hereunder upon such other party being notified in writing by the party alleging such failure and failing
to remedy such failure within 30 days of receiving such notice.

 

		5.02	Termination
                                         by Corporation or Consultant on Notice

 

The
Corporation or the Consultant may terminate this Agreement upon the giving 30 days written notice to the other party. Notwithstanding
the foregoing, the Corporation may terminate this Agreement immediately upon providing the Consultant with payment of one month
fee for services in lieu of such notice.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

		5.03	Termination
                                         by Corporation when Payment Limit Reached

 

This
Agreement shall be terminated upon the Corporation giving the Consultant written notice that the total payment limit for this
Agreement as set forth in Section 2.04 hereof has been reached.

 

		5.04	Termination
                                         on Death of Consultant

 

This
Agreement shall be terminated upon the death of the Consultant.

 

		5.05	Provisions
                                         which Operate Following Termination

 

Notwithstanding
any termination of this Agreement for any reason whatsoever and with or without cause, the provisions of Sections 3.06, 3.07,
3.08 and 3.09 and any other provisions of this Agreement necessary to give efficacy thereto shall continue in full force and effect
following any such termination.

 

ARTICLE
Six - INTERPRETATION AND ENFORCEMENT

 

		6.01	Sections
                                         and Headings

 

The
division of this Agreement into Articles and Sections and the insertion of headings are for the convenience of reference only
and shall not affect the construction or interpretation of this Agreement. The terms “this Agreement”, “hereof”,
“hereunder” and similar expressions refer to this Agreement and not to any particular Article, Section or other portion
hereof and include any agreement or instrument supplemental or ancillary hereto. Unless something in the subject matter or context
is inconsistent therewith, references herein to Articles and Sections are to Articles and Sections of this Agreement.

 

		6.02	Number

 

In
this Agreement words importing the singular number only shall include the plural and vice versa and words importing the
masculine gender shall include the feminine and neuter genders and vice versa and words importing persons shall include
individuals, partnerships, associations, trusts, unincorporated organizations and corporations and vice versa.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

		6.03	Benefit
                                         of Agreement

 

This
Agreement shall enure to the benefit of and be binding upon the heirs, executors, administrators and legal personal representatives
of the Consultant and the successors and assigns of the Corporation respectively.

 

		6.04	Entire
                                         Agreement

 

This
Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and cancels and supersedes
any prior understandings and agreements between the parties hereto with respect thereto. There are no representations, warranties,
forms, conditions, undertakings or collateral agreements, express implied or statutory between the parties other than as expressly
set forth in this Agreement.

 

		6.05	Amendments
                                         and Waivers

 

No
amendment to this Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties hereto.
No waiver of any breach of any term or provision of this Agreement shall be effective or binding unless made in writing and signed
by the party purporting to give the same and, unless otherwise provided in the written waiver, shall be limited to the specific
breach waived.

 

		6.06	Assignment

 

Except
as may be expressly provided in this Agreement, neither party hereto may assign his or its rights or obligations under this Agreement
without the prior written consent of the other party hereto.

 

		6.07	Severability

 

If
any provision of this Agreement is determined to be invalid or unenforceable in whole or in part, such invalidity or unenforceability
shall attach only to such provision or part thereof and the remaining part of such provision and all other provisions hereof shall
continue in full force and effect.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

		6.08	Notices

 

Any
demand, notice or other communication (hereinafter in this Section 6.08 referred to as a “Communication”) to be made
or given in connection with this Agreement shall be made or given in writing and may be made or given by personal delivery or
by registered mail addressed to the recipient as follows:

 

To
the Consultant:

 

●
Dr. Stephen Haworth

 

1901
Yardley Road

 

Yardley,
PA 19067

 

Phone
number: 1-215-850-1329

 

Email:
shaworth@haworthbiopharma.com

 

To
the Corporation:

 

XORTX
Therapeutics Inc

 

Suite
4000, 421 – 7th Avenue, Calgary, Alberta, Canada

 

adavidoff@xortx.com

 

403-607-2621

 

Attention:
Dr. Allen Davidoff

 

or
such other address or individual as may be designated by notice by either party to the other. Any Communication made or given
by personal delivery shall be conclusively deemed to have been given on the day of actual delivery thereof and, if made or given
by registered mail, on the ● day, other than a Saturday, Sunday or statutory holiday in Ontario, following the deposit
thereof in the mail. If the party giving any Communication knows or ought reasonably to know of any difficulties with the postal
system which might affect the delivery of the mail, any such Communication shall not be mailed but shall be made or given by personal
delivery.

 

		6.09	Governing
                                         Law

 

This
Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable
therein.

 

		6.10	Attornment

 

For
the purpose of all legal proceedings this Agreement shall be deemed to have been performed in the Province of Ontario and the
courts of the Province of Ontario shall have jurisdiction to entertain any action arising under this Agreement. The Corporation
and the Consultant each hereby attorns to the jurisdiction of the courts of the Province of Ontario provided that nothing herein
contained shall prevent the Corporation from proceeding at its election against the Consultant in the courts of any other province
or country.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

		6.11	Copy
                                         of Agreement

 

The
Consultant hereby acknowledges receipt of a copy of this Agreement duly signed by the Corporation.

 

IN
WITNESS WHEREOF the parties have executed this Agreement.

 

	SIGNED, SEALED AND DELIVERED	 	)	 	 
	in the presence of:	 	)	 	 
	 	 	)	 	 
	 	 	)	 /s/ Dr. Stephen Haworth	 
	Witness	 	)	Dr. Stephen Haworth

shaworth@haworthbiopharma.com	 
	 	 	 	 	 
	 	 	Per:	 /s/ Dr. Allen Davidoff	 
	 	 	 	Dr. Allen Davidoff, CEO and President	 
	 	 	 	 	 
	 	 	 	XORTX
    Therapeutics Inc.	 

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

Schedule
“A”

 

Position
Summary: The Chief Medical Officer will report directly to the Chief Executive Officer. The primary role of the CMO will be
to provide leadership and direction for XORTX’s pipeline of clinical development programs in genetic rare disease Autosomal
Dominant Polycystic Kidney Disease (ADPKD) , acute kidney injury due to COVID infection and diabetic nephropathy (DN). The CMO
will be responsible for the strategy, direction and execution of the company’s clinical development plans. The CMO will
be a key member of the senior management team as a member of the company’s Executive Committee which determines and oversees
research and drug development at XORTX and sets the overall strategic direction of the company. This is a unique opportunity to
be a major contributor to the success of a well-positioned, well-financed growth stage biotechnology company.

 

Essential
Duties and Responsibilities:

To
perform this job successfully, an individual must be able to perform the following:

●
Direct the development of clinical strategies and plans to integrate XORTX Therapeutics Inc. compounds into the standard practice
of nephrology and (genetic rare diseases

●
Orchestrate and manage clinical aspects of regulatory strategies and interactions with Health Authorities

●
Oversee the analysis and interpretation of clinical trial data and the reporting of clinical trial results Chief Medical Officer

●
Lead interactions with academic thought leaders, investigators, cooperative groups, and other clinical stakeholders

●
Provide clinical support and work with other members of the management team to develop and communicate the overall corporate strategy

●
Represent the Company and its programs to external audiences, including the investment, medical and regulatory communities, as
well as pharmaceutical or biotechnology industry collaborators/partners

●
In addition to leading and supervising the Clinical Research Department the CMO will have direct line responsibility for the Clinical
Operations, Patient Advocacy, Medical Affairs, and Biometrics Departments

 

Qualifications:

Education/Experience:
The ideal candidate will offer:

●
MD with Board Certification in nephrology or cardiovascular training preferred

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

 

●
15 years minimum experience in clinical practice treating patients and pharmaceutical and/or biotechnology industry experience
as a sponsor working on investigational new drugs.

●
Multiple years of management experience leading a clinical group including clinical/medical affairs and clinical operations

●
A proven success record in Phase I-IV clinical research studies and trial design as well as the successful submission of IND’s
and marketing approval-directed filings (BLA’s, NDA’s, and MAA’s)

 

Knowledge,
Skills and Abilities:

●
Knowledge of relevant FDA regulations and guidelines as well as those of the US, EU and other health authorities; experience in
interactions with FDA personnel is essential; experience in interactions with other health authorities a plus

●
Experience with, or strong knowledge of drug development

●
Experience or knowledge of Orphan or genetic rare disease drug development a plus

●
Experience in translational medicine, clinical pharmacology and early stage development is desirable

●
Excellent knowledge of the competitive environment for drugs in the Nephrology, Diabetes and Cardiovascular marketplace and in
research and development pipelines

●
Must have a thorough knowledge of clinical research concepts, practices, and GCP and ICH Guidelines.

● The successful candidate
will read, write and speak fluent English, possess excellent communication skills and will be capable of articulating the Company’s
clinical and regulatory strategies and progress to a wide audience including the CEO, the Board of Directors, Company employees,
and the investor community.

●
Must have excellent leadership and interpersonal skills; should have proven skills as an effective team player who can engender
credibility and confidence within and outside the company; must have outstanding executive presence.

●
Must be science- and data-driven

●
For best fit, the candidate must have the ability and strong desire to “make things happen”.

Chief
Medical Officer - Must have a results-oriented work ethic and a positive, can-do attitude. Effective leadership, people management,
communication skills and a team builder management style are essential; must be willing and able to be “hands on”.

●
Must have the highest personal values and ethical standards.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

 

 

Work
Environment: This is a high growth, fast paced small organization. The ability to be productive and successful in an intense
work environment is critical. Willingness and ability to travel domestically and internationally is required, it is anticipated
that this will be 30 % of work time.

 

Physical
Demands: The physical demands described here are representative of those that must be met by an employee to successfully perform
the essential functions of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform
the essential functions. The above job description is not intended to be an all-inclusive list of duties and standards of the
position. Incumbents will follow any other instructions, and perform any other related duties, as assigned by their supervisor.

 

	 	XORTX
        Therapeutics Inc.

        4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9

         

        T
        + 1 403 455 7717  | 
        xortx.com  | 
        CSE : XRX  |  OTCQB : XRTXF

 

     

     

    

 

TABLE
OF CONTENTS

 

CONSULTING
AGREEMENT

 

	ARTICLE ONE - GENERAL	1
	 	 
	1.01	Consultant Services	1
	1.02	Term of Agreement	1
	 	 	 
	ARTICLE TWO - REMUNERATION OF CONSULTANT	2
	 	 
	2.01	Fee for Services	2
	2.02	Expenses	2
	2.03	Invoices	2
	2.04	Total Payment	3
	 	 	 
	ARTICLE THREE - COVENANTS OF CONSULTANT	3
	 	 
	3.01	Services	3
	3.02	Time of Services	3
	3.03	Licences and Permits	3
	3.04	Rules and Regulations	3
	3.05	Insurance	4
	3.06	Indemnity	4
	3.07	Non-disclosure	4
	3.08	Non-Competition	5
	3.09	Inventions and Patents	5
	 	 	 
	ARTICLE FOUR - INDEPENDENT CONTRACTORS	6
	 	 
	4.01	Consultant not an Employee	6
	4.02	Consultant shall not contract on behalf of Corporation	6
	 	 	 
	ARTICLE FIVE - TERMINATION	6
	 	 
	5.01	Termination by Corporation or Consultant for
    Cause	6
	5.02	Termination by Corporation or Consultant on
    Notice	6
	5.03	Termination by Corporation when Payment Limit
    Reached	7
	5.04	Termination on Death of Consultant	7
	5.05	Provisions which Operate Following Termination	7
	 	 	 
	ARTICLE SIX - INTERPRETATION AND
    ENFORCEMENT	7
	 	 
	6.01	Sections and Headings	7
	6.02	Number	7
	6.03	Benefit of Agreement	8
	6.04	Entire Agreement	8
	6.05	Amendments and Waivers	8
	6.06	Assignment	8
	6.07	Severability	8
	6.08	Notices	9
	6.09	Governing Law	9
	6.10	Attornment	9

 

     

     

    

 

 

 

	6.11	Copy of
    Agreement	10

 

	 	 
	Labour Department Precedent	LA02_001.WPD
	Consulting Agreement Master	(formerly TOR-ELM\1039)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]